BrainStorm

News

News

Press Releases

Date Title and Summary Additional Formats
Toggle Summary BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society
NEW YORK , Nov. 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that the Company has received a $495,330 grant from the National Multiple Sclerosis Society , through
View HTML
Toggle Summary BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: ALS Phase 3 Clinical Trial Fully Enrolled, Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue, Appointment of CFO, Phase 2 in Progressive MS Continues to Enroll Patients   NEW YORK , Nov.
View HTML
Toggle Summary BrainStorm Announces Grant of a New Japanese Patent for NurOwn®
NEW YORK , Nov. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japan Patent Office (JPO) has issued a Decision to Grant a Patent for BrainStorm's Patent
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting
NEW YORK , Nov. 12, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company’s Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7 th
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update
NEW YORK , Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the third
View HTML
Toggle Summary NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue
NEW YORK , Oct. 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Phase 3 clinical trial independent Data Safety Monitoring Board (DSMB) has completed the
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
NEW YORK , Oct. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that it will be presenting at the Dawson James Securities 5th
View HTML
Toggle Summary BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019
NEW YORK , Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced, Chaim Lebovits , President and CEO, will serve as a Keynote
View HTML
Toggle Summary BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit
NEW YORK , Oct. 23, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will be participating and presenting scientific data at the upcoming
View HTML
Toggle Summary BrainStorm’s NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled
NEW YORK , Oct. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc . ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it has fully enrolled the 200-patient Phase 3 clinical trial evaluating repeat intrathecal
View HTML
Toggle Summary BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform
NEW YORK , Oct. 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United States Patent and Trademark Office ( USPTO ) has issued a Notice of Allowance for
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting
NEW YORK , Oct. 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases announced today, Chief Operating Officer and Chief Medical Officer, Ralph Kern
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development
BrainStorm Holds a Roundtable Discussion with ALS Advocacy Group Leaders   NEW YORK , Sept. 27, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases
View HTML
Toggle Summary BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer
NEW YORK , Sept. 09, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that Preetam Shah , Ph.D., M.B.A., has been appointed Chief Financial Officer effective September 6 ,
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress
NEW YORK , Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will present scientific data at the 35 th Congress of the European Committee
View HTML
Toggle Summary BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update
Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: Special High -level FDA Meeting, Continued Progress in NurOwn ® ALS Phase 3 Trial and Progressive MS Phase 2 Trial, ALS Phase 3 Trial Enrollment Update NEW YORK , Aug. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update
Tuesday, August 13, 2019, 8:00 a.m. EDT NEW YORK , Aug. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today, that the Company will hold a
View HTML
Toggle Summary Third Clinical Site Initiated for BrainStorm Cell Therapeutic’s Phase 2 Progressive MS Study
NEW YORK , July 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company has contracted with the Keck School of Medicine of
View HTML
Toggle Summary BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting
Design of Phase 2 Open-Label Multicenter Study in Progressive MS Outlined NEW YORK and SEATTLE , May 31, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,
View HTML
Toggle Summary BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
NEW YORK , May 30, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that the Stanford University School of Medicine will serve as the
View HTML
Toggle Summary BrainStorm Issues Statement (Italian Translation Included)
Toggle Summary BrainStorm Senior Management to Present at BIO 2019
- Chaim Lebovits , President & CEO Corporate Presentation, June 4, 2019 -  - Ralph Kern MD, MHSc, Chief Medical Officer & Chief Operating Officer Round Table Panelist, June 4, 2019 - NEW YORK , May 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and LONDON , May 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( Nasdaq: BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , president and CEO, will provide an update on the Company’s two
View HTML
Toggle Summary BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update
Highlights Scientific Advances and Continued Progress in NurOwn ® ALS Phase 3 Trial  and Progressive MS Phase 2 Trial; Expansion of the proprietary cellular technology platform NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases
NEW YORK , April 30, 2019 (GLOBE NEWSWIRE) -- Brainstorm-Cell Therapeutics Inc. , ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced that it has expanded its proprietary cellular technology platform to include NurOwn®-derived
View HTML
Toggle Summary Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting
Abstracts to highlight NurOwn® mechanism of action and correlation of Phase 2 clinical outcomes with ALS disease biomarkers NEW YORK , March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly
View HTML
Toggle Summary BrainStorm Announces Grant of an additional New European Patent for NurOwn®
NEW YORK , March 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has granted a European-wide patent titled 'Mesenchymal Stem
View HTML
Toggle Summary BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
Enrollment Announced During MS Awareness Week NEW YORK and CLEVELAND , March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the
View HTML
Toggle Summary BrainStorm to Host Business Update Conference Call
Tuesday, March 12th at 8.30am EDT NEW YORK , March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will hold a conference call on Tuesday, March 12
View HTML
Toggle Summary BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study
Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019 NEW YORK and CLEVELAND , Feb. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular
View HTML
Toggle Summary BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland
ZURICH, Switzerland and NEW YORK , Feb. 21, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO will present at the
View HTML
Toggle Summary BrainStorm Issues a Statement to Patients and Shareholders
NEW YORK , Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, in response to numerous requests, issues today the following statement: We will begin by
View HTML
Toggle Summary BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium
NEW YORK , Feb. 04, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO, will provide a corporate presentation at the
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida
NEW YORK , Jan. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO will provide a corporate overview presentation
View HTML
Toggle Summary BrainStorm Granted Additional Patent for NurOwn® in Israel
NEW YORK , Jan. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office has granted an additional patent titled “Methods
View HTML
Toggle Summary BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
Dr. Ralph Kern to Provide Update on the Phase 3 Pivotal Trial of Autologous MSC-NTF Cellular Therapy (NurOwn®) in ALS   NEW YORK and IRVINE, Calif. , Jan. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week
NEW YORK , Jan. 03, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , President and Chief Executive Officer, will provide a corporate overview at the
View HTML
Toggle Summary BrainStorm Issues 2018 Letter to Shareholders
NEW YORK , Dec. 27, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. Dear Valued Shareholder, This past year was an extraordinary success for
View HTML
Toggle Summary BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial
BrainStorm has contracted with the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute, currently supporting the Phase 3 ALS Trial, to Produce NurOwn® NEW YORK and BOSTON , Dec. 26, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI),
View HTML
Toggle Summary FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
U.S. Phase 2 Study to Begin in First Quarter of 2019     NEW YORK , Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that the
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND
Poster highlights enrichment strategies for clinical trials in ALS NEW YORK , Dec. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis
NEW YORK , Nov. 19, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, today announced that it has submitted an Investigational New Drug (IND) application
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences
Highlights Preclinical Research and Continued Progress of NurOwn® Platform in ALS Pivotal Trial NEW YORK and PETACH TIKVAH, Israel , Nov. 07, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for
View HTML
Toggle Summary BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
Highlights Scientific Advances and Continued Progress for NurOwn ® in ALS Towards U.S. FDA Approval; Following Successful FDA Pre-IND Meeting, BrainStorm will File an IND for NurOwn ® in a Second Clinical Indication Conference Call and Webcast Today at 8:30am Eastern Time NEW YORK , Oct.
View HTML
Toggle Summary BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29
Conference Call and Live Webcast at 8:30am Eastern Time NEW YORK and PETACH TIKVAH, Israel , Oct. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for
View HTML
Toggle Summary BrainStorm Poster Receives Clinical Abstract Award at NEALS Conference
Translational Insights Support NurOwn ® as a Best-In-Class Strategy in ALS NEW YORK and PETACH TIKVAH, Israel , Oct. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating
View HTML
Toggle Summary BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS
NurOwn® to be Featured at NEALS and Cell & Gene Meeting on the Mesa Conferences NEW YORK and PETACH TIKVAH, Israel , Oct. 03, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative adult stem cell therapeutics for debilitating neurodegenerative
View HTML
Toggle Summary BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn®
NEW YORK and PETACH TIKVAH, Israel , Sept. 13, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the United States Patent Office (USPTO) has granted a new US patent
View HTML
Toggle Summary BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform
NEW YORK and PETACH TIKVAH, Israel , Sept. 12, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for debilitating neurodegenerative diseases, announced today that members of BrainStorm’s executive team will present and
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference
Presentation and Live Webcast on Thursday, September 6th, 2.10pm ET NEW YORK and PETACH TIKVAH, Israel , Sept. 05, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the
View HTML
Toggle Summary BrainStorm Appoints Arturo Araya as Chief Commercial Officer
Mr. Araya was Global Head of Commercial of Novartis Cell & Gene Therapies Unit Appointment strengthens leadership team with nearly 20 years of global pharmaceutical marketing and commercialization experience NEW YORK and PETACH TIKVAH, Israel, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference
NEW YORK and PETACH TIKVAH, Israel , Aug. 29, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the H.C.
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALS
NEW YORK , and PETACH TIKVA, Israel , Aug. 23, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has completed the
View HTML
Toggle Summary BrainStorm Announces Grant of a New European Patent for NurOwn®
NEW YORK and PETACH TIKVAH, Israel, July  25, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has granted an European-wide patent
View HTML
Toggle Summary BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update
Conference Call and Webcast at 8.30am ET Today NEW YORK and PETACH TIKVAH, Israel , July 23, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the second
View HTML
Toggle Summary BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23
Conference Call and Live Webcast at 8.30am ET NEW YORK and PETACH TIKVAH, Israel , July 17, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the second
View HTML
Toggle Summary BrainStorm Granted Japanese Patent for NurOwn®
NEW YORK and PETACH TIKVAH, Israel, July 5, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has received a Decision to Grant notice from the Japanese Patent Office
View HTML
Toggle Summary BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production
NEW YORK , PETACH TIKVA, Israel and BOSTON , July 2, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has contracted with the Connell and O'Reilly Families Cell
View HTML
Toggle Summary BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Susan Ward, Ph.D. (Pfizer) Appointed Head of Clinical Operations Joe Petroziello (Juno Therapeutics) Appointed VP of Scientific & Corporate Communications NEW YORK and PETACH TIKVAH, Israel, June 28, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm Provides Update on "Right to Try" Policy
  Webcast and Conference Call at 8:30am Eastern Time Today NEW YORK and PETACH TIKVA, Israel , June 26, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that after careful
View HTML
Toggle Summary BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy
Conference Call and Live Webcast at 8:30am Eastern Time NEW YORK and PETACH TIKVAH, Israel , June 25, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call tomorrow,
View HTML
Toggle Summary BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share
NEW YORK and PETACH TIKVA, Israel , June 7, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a Warrant Exercise Agreement with certain holders of warrants
View HTML
Toggle Summary BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing
Conference call and live webcast on June 7th at 8:15am EDT NEW YORK and PETACH TIKVAH, Israel, June 1, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that the company will
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention
NEW YORK and PETACH TIKVAH, Israel , May 30, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present a corporate overview at the BIO International
View HTML
Toggle Summary BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation
NEW YORK and PETACH TIKVAH, Israel , May 25, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issues a statement following Congress passing the Federal "Right-to-Try" bill.
View HTML
Toggle Summary BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights
Call Today and Webcast @ 8:30am Eastern Time Today NEW YORK, N.Y. and PETACH TIKVAH, Israel , May 14, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today financial results for the
View HTML
Toggle Summary BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and PETACH TIKVAH, Israel , May 9, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , president and CEO, will present data from the company's Phase
View HTML
Toggle Summary Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14
Conference Call and Live Webcast at 8:30am Eastern Time NEW YORK and PETACH TIKVAH, Israel , May 8, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call to discuss its
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference
NEW YORK and PETACH TIKVAH, Israel , May 1, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that Ralph Kern , M.D., MHSc, Chief Operating Officer and Chief Medical Officer, will
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
NEW YORK and PETACH TIKVAH, Israel , April 11, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will present at the Alliance for
View HTML
Toggle Summary Letter To Shareholders
Toggle Summary BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients
Canada-Based ALS Patients Can Be Enrolled at The University of Massachusetts NEW YORK and PETACH TIKVAH, Israel , March 28, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announces that
View HTML
Toggle Summary BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 21, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced the appointments of Stanley H.
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum
HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 15, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief Executive Officer, and Dr.
View HTML
Toggle Summary BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 12, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the formation of its Scientific Advisory Board (SAB) and the appointment
View HTML
Toggle Summary BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
Conference Call and Webcast @ 8:30 a.m. Eastern Time Today NEW YORK and PETACH TIKVAH, Israel , March 8, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for
View HTML
Toggle Summary BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8
HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 5, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call on Thursday, March 8 to discuss financial results for the
View HTML
Toggle Summary BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 7, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing ALSFRS-R subgroup analyses and
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 6, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , President & Chief Executive Officer, will provide a
View HTML
Toggle Summary BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 5, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the appointment of Anthony (Tony) Polverino , Ph.D., to its board of
View HTML
Toggle Summary BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22
HACKENSACK, N.J. and PETACH TIKVA, Israel , Jan. 16, 2018 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits , President & CEO, and Dr.
View HTML
Toggle Summary BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®
HACKENSACK, N.J. and PETACH TIKVA, Israel , Jan. 3, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has received Good Manufacturing Practice (GMP) approval from the Israel
View HTML
Toggle Summary Brainstorm Issues 2017 Letter to Shareholders
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 29, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to Shareholders from its President and CEO, Chaim Lebovits Dear
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 20, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Toggle Summary BrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 29, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing innovative biomarker data from the
View HTML
Toggle Summary New Peer Reviewed Publication Shows That BrainStorm's NurOwn® Has a Unique miRNA Signature
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Nov. 9, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that a study profiling NurOwn ® 's unique miRNA signature has been
View HTML
Toggle Summary BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
Eyal Rubin, VP and Head of Corporate Treasury at Teva, is Third Senior Appointment at Brainstorm in 2017 HACKENSACK, N.J. and PETACH TIKVAH, Israel , Nov. 2, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for
View HTML
Toggle Summary BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinson's Disease And ALS
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 23, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has received Notice of Allowance from the United States Patent Office
View HTML
Toggle Summary BrainStorm Announces Third Quarter 2017 Financial Results
Conference Call with Management to Discuss Recent Corporate Progress at 8:30am Eastern Time Today HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 17, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative
View HTML
Toggle Summary BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS
Trial supported by a $16M non-dilutive grant from CIRM Top-line data are expected in 2019 HACKENSACK, N.J. and PETACH TIKVA, Israel , Oct. 16, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that the first patients have been enrolled in the Phase 3 clinical
View HTML
Toggle Summary Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17
Conference Call and Live Webcast at 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 3, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases , will announce financial results
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Sept. 27, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases announced today that it will be presenting at the 2017 Disruptive Growth Company Showcase
View HTML
Toggle Summary BrainStorm Announces Second Quarter 2017 Financial Results
Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 15, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for
View HTML
Toggle Summary Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 10, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases , will announce financial results for the three and six months ended June 30, 2017 and
View HTML
Toggle Summary BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
Mary Kay Turner brings 25+ years Biotech and Pharmaceutical Experience in Healthcare Advocacy and Policy; Prior Positions Include Head of Patient Advocacy and Communications at Mitsubishi Tanabe Pharma America and Head of State Government Affairs and Advocacy at Bristol-Myers Squibb Company
View HTML
Toggle Summary BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel , July 25, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement with the University of
View HTML
Toggle Summary Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel , July 21, 2017 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded
View HTML
Toggle Summary BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVA, Israel , July 18, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed definitive agreements with Massachusetts General
View HTML
Toggle Summary Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALS
HACKENSACK, N.J. and PETACH TIKVAH, Israel , July 3, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has selected Worldwide Clinical Trials ("Worldwide") as its
View HTML
Toggle Summary BrainStorm to Provide Corporate Update at the BIO International Convention
HACKENSACK, N.J. and PETACH TIKVAH, Israel , June 14, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company will present a corporate overview at the BIO
View HTML
Toggle Summary BrainStorm Awarded $2.1 Million Non-Dilutive Grant for 2017 by the Israel Innovation Authority
HACKENSACK, N.J. and PETACH TIKVAH, Israel , June 13, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd.
View HTML
Toggle Summary BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 22, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the Company will present data from its Phase 2 clinical study of NurOwn® in
View HTML
Toggle Summary BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study
HACKENSACK, N.J. , PETACH TIKVA, Israel and DUARTE, Calif. , May 16, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has begun training the cell manufacturing team at
View HTML
Toggle Summary BrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 15, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the first quarter ending March 31, 2017 .
View HTML
Toggle Summary BrainStorm to Present at Two Scientific Conferences in May
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 1, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present data from its Phase 2 clinical study of
View HTML
Toggle Summary Brainstorm Cell Therapeutics to Present at ARM's 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
HACKENSACK, N.J. and PETACH TIKVAH, Israel , April 20, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will present at the
View HTML
Toggle Summary BrainStorm Announces Publication of NurOwn® Autism Research Study
Preclinical Findings Show Potential for Human Benefit HACKENSACK, N.J. and PETACH TIKVAH, Israel , April 19, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that a preclinical
View HTML
Toggle Summary BrainStorm Announces Financial Results for 2016 and Provides Business Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 30, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the year ended December 31, 2016 .
View HTML
Toggle Summary BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 22, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide an update on
View HTML
Toggle Summary BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
Brings 10+ years Biotech and Pharmaceutical Industry Experience; Prior Academic Positions Include Consultant Neurologist Role at Mount Sinai Hospital, Toronto, Canada. HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 6, 2017 /CNW/ --  BrainStorm Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm Announces MOU with Tel Aviv Sourasky Medical Center to Make NurOwn® Available to Patients as a Hospital Exemption Product
Tel Aviv Sourasky Medical Center (Ichilov) Is Also Expected to be a Treatment Center in Planned Phase 3 Trial of NurOwn In ALS HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 1, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell
View HTML
Toggle Summary BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 27, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointments of June S. Almenoff , M.D., Ph.D., FACP, and Arturo O.
View HTML
Toggle Summary BrainStorm Seeking Approval To Distribute NurOwn® in Canada
Signs agreement with CCRM for regulatory support of ALS treatment TORONTO , HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 21, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, has signed an
View HTML
Toggle Summary City of Hope to Manufacture NurOwn® for Brainstorm's Phase 3 ALS Clinical Trial
HACKENSACK, N.J. and PETACH TIKVA, Israel and DUARTE, Calif. , Feb. 16, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it plans to contract with City of Hope's Center for
View HTML
Toggle Summary BrainStorm CEO to Present at the BIO CEO & Investor Conference
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Feb. 6, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Toggle Summary BrainStorm Announces Validation of NurOwn® Cryopreservation Process
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Jan. 30, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has validated its cryopreservation process for NurOwn ® in preparation
View HTML
Toggle Summary BrainStorm CEO to Present at the Phacilitate Cell & Gene Therapy World Conference 2017 in Miami
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Jan. 17, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will give a presentation
View HTML
Toggle Summary BrainStorm CEO to Present at the 9th Annual Biotech Showcase
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Jan. 5, 2017 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Toggle Summary Brainstorm Reports on Successful End of Phase 2 Meeting with FDA, Upcoming Phase 3 Trial and Planned Application for Hospital Exemption for NurOwn®
Conference Call @ 8:30am Eastern Time Today to Provide Corporate Update and Discuss Plans for 2017 HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 19, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative
View HTML
Toggle Summary 21st Century Cures Act Passed by U.S. Congress Provides an Accelerated Approval Pathway for Regenerative Medicine Therapies
Legislation Potentially Has Direct and Positive Implications for NurOwn® HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 15, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced its
View HTML
Toggle Summary In-Depth Analyses Presented at International Symposium on ALS/MND Suggest Strong Biological Effect for NurOwn®; Evidence of Halting of Disease Progression
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 14, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that new data from the Company's Phase 2 study of NurOwn ® in ALS were presented by lead
View HTML
Toggle Summary BrainStorm to Host Year End Call with Investors to Discuss Important Corporate Developments
Company Explores Regulatory Commercial Pathways for NurOwn® Conference Call and Live Webcast on December 19 at 8:30 am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 6, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell
View HTML
Toggle Summary BrainStorm Announces NurOwn® Data to be Highlighted at the 27th International Symposium on ALS/MND
Clinical Data to be Presented by James D. Berry, MD, MPH, and Anthony J. Windebank, MD, Principal Investigators in NurOwn® Phase 2 Trial HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 5, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reports Third Quarter 2016 Financial Results
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Nov. 15, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter
View HTML
Toggle Summary BrainStorm Granted United States Patent for its Stem Cell Technology
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Oct. 31, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.  (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has been granted United States Patent No.
View HTML
Toggle Summary BrainStorm CEO to Present at Two Investor Conferences in September
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Sept. 6, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Toggle Summary BrainStorm CEO to Present at Two Investor Conferences in September
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Sept. 6, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , Chief Executive Officer, will provide a corporate
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 11, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter
View HTML
Toggle Summary BrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS)
NurOwn® was Demonstrated to be Safe and Well Tolerated Clinically Meaningful Benefit Demonstrated by Higher Response to NurOwn® Compared to Placebo at All Time Points Conference Call and Live Webcast at 10am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 18, 2016 /PRNewswire/ --
View HTML
Toggle Summary BrainStorm to Announce Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) on Monday, July 18
Conference Call and Live Webcast at 10am Eastern Time HACKENSACK, N.J. and PETACH TIKVAH, Israel , July 14, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce results from the
View HTML
Toggle Summary BrainStorm to Present at World Stem Cells & Regenerative Medicine Congress in London
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 17, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits , Chief Executive Officer, will be presenting Thursday,
View HTML
Toggle Summary BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2016 from Israel's Office of the Chief Scientist
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 12, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd.
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , May 10, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter
View HTML
Toggle Summary Brainstorm to Present at the ISRASTEM 2016 and the 6th International Israel Stem Cell Society Joint Annual Meeting
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 29, 2016 /PRNewswire/ --  Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Dr. Yael Gothelf , VP Scientific & Regulatory Affairs will be
View HTML
Toggle Summary BrainStorm Announces Financial Results for 2015 and Provides Business Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , March 10, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2015
View HTML
Toggle Summary BrainStorm to Present at Bio-Asia-International and ARM Investor Day Conferences
NEW YORK and PETACH TIKVAH, Israel , March 8, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits , Chief Executive Officer, will be presenting at two upcoming
View HTML
Toggle Summary BrainStorm's NurOwn® for the Treatment of ALS Published in JAMA Neurology
Clinical Data Suggest that NurOwn Can Slow Disease Progression in ALS First Human Experience With Stem Cells Induced Under Culture to Produce Neurotrophic Factors (NTFs) Conference Call Today at 10:45am ET / 7:45am PT HACKENSACK, N.J. and PETACH TIKVAH, Israel , Jan.
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Conduct Phase 2 Multi-Dose NurOwn® Trial in ALS at Hadassah Medical Center
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Jan. 11, 2016 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has entered into a collaborative agreement with Hadassah Medical
View HTML
Toggle Summary BrainStorm Reschedules Corporate Update Conference Call to January 11, 2016
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 10, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has rescheduled its conference call, originally scheduled for
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 7, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Dr. Revital Geffen-Aricha, M.Sc., Ph.D., as Vice
View HTML
Toggle Summary BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 2, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will hold a conference call on Wednesday, December 16, 2015 at 8:45
View HTML
Toggle Summary BrainStorm and Octane Biotech Announce Success in Cocoon™ Application Development Based on Customized Bioreactor for NurOwn® Stem Cells
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Dec. 1, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc. , a Canadian company that focuses on clinical systems for cell and
View HTML
Toggle Summary BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israel's Office of the Chief Scientist
New Grant is the Second Awarded by OCS to Brainstorm in 2015 HACKENSACK, N.J. and PETACH TIKVAH, Israel , Nov. 30, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Nov. 17, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the third quarter
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Positive DSMB Review in Phase 2 Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Nov. 9, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Data and Safety Monitoring Board (DSMB) conducted its second
View HTML
Toggle Summary BrainStorm Strengthens Intellectual Property Position - Granted Patent for Company's NurOwn® Technology Platform
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 16, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company has been granted a patent by the Israeli Patent Office
View HTML
Toggle Summary BrainStorm Cell Therapeutics' Chief Scientific Advisor to Present At The 2015 FENS-RM in Thessaloniki, Greece
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 8, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announces that its Chief Scientific Advisor, Prof Daniel Offen , PhD, will be presenting
View HTML
Toggle Summary BrainStorm Announces Treatment of Final Patient in US Multicenter Double Blinded Phase 2 ALS Trial
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 7, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the final patient has been treated in its multicenter Phase 2 clinical
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Oct. 1, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting at the annual Partnering Forum , part of the Stem Cell Meeting on the
View HTML
Toggle Summary BrainStorm Announces Appointment of Chaim Lebovits as Chief Executive Officer
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Sept. 22, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Mr.
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at Rodman & Renshaw 17th Annual Global Investment Conference
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Sept. 2, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino , MD, PhD, will present a
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 13, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of NurOwn® in ALS
HACKENSACK, N.J. and PETACH TIKVAH, Israel , Aug. 11, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has completed enrollment in its ongoing randomized, double-blind
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13
NEW YORK and PETACH TIKVAH, Israel , Aug. 6, 2015 /PRNewswire/ --  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report second quarter 2015 financial results on Thursday, August 13 ,
View HTML
Toggle Summary BrainStorm Strengthens Executive Team: Announces the Appointment of Yoram Bibring as Chief Financial Officer
Hackensack, NJ and Petach Tikvah, Israel -- August 3, 2015 – BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Yoram Bibring as Chief Financial Officer, effective July 30,2015. 
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at Cantor Fitzgerald’s Inaugural Healthcare Conference
HACKENSACK, N.J. and PETACH TIKVAH, Israel , July 6, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at
View HTML
Toggle Summary BrainStorm Cell Therapeutics Added to Russell Microcap® Index
HACKENSACK, N.J. and PETACH TIKVAH, Israel , June 29, 2015 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that has been added to the Russell Microcap® Index.  The Russell indexes are
View HTML
Toggle Summary BrainStorm Cell Therapeutics at the BIO International Convention
HACKENSACK, N.J. and PETACH TIKVAH, Israel , June 16, 2015 -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is participating in the Israel Pavilion at the invitation of Israel’s Office of the Chief Scientist. 
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces First Quarter 2015 Financial Results and Provides Corporate Update
HACKENSACK, N.J. and PETACH TIKVAH, Israel – May 14, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31,
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at Upcoming Conferences
HACKENSACK, New Jersey and PETACH TIKVAH, Israel – May 11, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Yael Gothelf, Vice President, Scientific and Regulatory Affairs, will be
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
NEW YORK and PETACH TIKVAH, Israel – May 7, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report first quarter 2015 financial results on Thursday, May 14, 2015.  The Company
View HTML
Toggle Summary BrainStorm's NurOwn® Demonstrates a Statistically Significant Effect in ALS Patients
Phase 2a Results and New Analyses Presented at American Academy of Neurology HACKENSACK, New Jersey and PETACH TIKVAH, Israel – April 21, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data at American Academy of Neurology Annual Meeting
HACKENSACK, New Jersey and PETACH TIKVAH, Israel – April 14, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis
View HTML
Toggle Summary BrainStorm Announces Financial Results for 2014
Conference call today at 8.30 a.m. EDT HACKENSACK, New Jersey and PETACH TIKVAH, Israel – March 26, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26
Hackensack, NJ and Petach Tikvah, Israel – March 19, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report fourth quarter and full year 2014 financial results on Thursday,
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York
Hackensack, NJ & Petach Tikvah, Israel – March 18, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that CEO Tony Fiorino, MD, PhD ,will present at the 3rd Annual Regen Med Investor Day to be
View HTML
Toggle Summary BrainStorm Receives Notice of Allowance for its NurOwn™ Technology Platform from Israel’s Patent Office
Hackensack, NJ & Petach Tikvah, Israel – February 9, 2015, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from Israel’s Patent Office for its
View HTML
Toggle Summary BrainStorm CEO to Present at the 17th Annual BIO CEO & Investor Conference
Hackensack, NJ & Petach Tikvah, Israel – February 4, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chief Executive Officer Tony Fiorino, MD, PhD, will be presenting a corporate update
View HTML
Toggle Summary BrainStorm Announces Positive DSMB Recommendation in Ongoing Phase 2 Trial with NurOwn™ in ALS
No Concerns Identified; DSMB Recommends Trial Continues as Planned Hackensack, NJ & Petach Tikvah, Israel – February 3, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Data and
View HTML
Toggle Summary BrainStorm Announces Exceptional Preclinical Results of NurOwn™ in Mouse Autism Model
Hackensack, NJ & Petach Tikvah, Israel – January 26, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive results from preclinical studies of NurOwn™ in the BTBR mouse model of autism.
View HTML
Toggle Summary BrainStorm Enters Into Warrant Exercise Agreement for Approximately $13 Million in Proceeds
Warrant Holders Exercising at a Premium; to Receive New Warrants Hackensack, NJ & Petach Tikvah, Israel – January 8, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has entered into a
View HTML
Toggle Summary BrainStorm Announces Receipt of Approximately $3.1 Million from Warrant Exercises
NEW YORK, NY & PETACH TIKVAH, ISRAEL – January 7, 2015 - BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that since January 2, 2015 it has received approximately $3.1 million from the exercise of
View HTML
Toggle Summary BrainStorm CEO to Present at Two Upcoming Investor Conferences
NEW YORK, NY & PETACH TIKVAH, ISRAEL – January 6, 2015 - BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Tony Fiorino, MD, PhD, Chief Executive Officer, will be presenting at two upcoming
View HTML
Toggle Summary BrainStorm Announces Final Analysis of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit from NurOwn™
NEW YORK, NY & PETACH TIKVAH, ISRAEL – January 5, 2014 - BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn ™ in amyotrophic lateral
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Host Conference Call to Discuss Final Results of Phase 2a Trial of NurOwn™ in ALS on January 5, 2015
Safety and efficacy findings from interim analysis to be extended with additional data and analyses   NEW YORK, NY & PETACH TIKVAH, ISRAEL – December 22, 2014 - BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will
View HTML
Toggle Summary BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office
NEW YORK & PETACH TIKVAH, (Israel) – December 15, 2014 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd.
View HTML
Toggle Summary BrainStorm Announces Financial Results for the Third Quarter of 2014 and Provides Corporate Update
NEW YORK, PETACH TIKVAH (Israel) – November 13, 2014 - BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three and nine months ending September 30, 2014.
View HTML
Toggle Summary BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
NEW YORK and PETACH TIKVAH, Israel – November 5, 2014 –  BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report third quarter 2014 financial results on Thursday, November 13, 2014.  The
View HTML
Toggle Summary FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALS
NEW YORK, NY & PETACH TIKVAH, ISRAEL – October 7, 2014 - BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn™ as a Fast
View HTML
Toggle Summary BrainStorm Reports Last Patient Visit in Phase 2a ALS Study
NEW YORK, NY & PETACH TIKVAH, ISRAEL – October 6, 2014 – BrainStorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the last patient has completed the last visit in its phase 2a clinical trial of NurOwn™ in
View HTML
Toggle Summary BrainStorm Completes Uplisting to the NASDAQ Capital Market
NEW YORK & PETACH TIKVAH, (Israel) – September 30, 2014 - BrainStorm Cell Therapeutics Inc. (BCLI; BCLID), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital
View HTML
Toggle Summary BrainStorm Receives Approval for Uplisting to the NASDAQ Capital Market Expect Trading to Commence September 30, 2014
NEW YORK, NEW YORK & PETACH TIKVAH, ISRAEL – September 24, 2014 - BrainStorm Cell Therapeutics Inc. (BCLI; BCLID), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its shares of common stock have been approved for uplisting to the NASDAQ
View HTML
Toggle Summary BrainStorm Provides Update on NASDAQ Uplisting Process
NEW YORK & PETACH TIKVAH, (Israel) – September 9, 2014 - Brainstorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that on September 15, 2014, it plans to effect a 1 for 15 reverse split of its issued and
View HTML
Toggle Summary BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment Conference
NEW YORK, PETACH TIKVAH (Israel)  – September 4, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate overview of BrainStorm
View HTML
Toggle Summary BrainStorm Granted European Patent Covering its Stem Cells for the Treatment of CNS Diseases
NEW YORK, PETACH TIKVAH (Israel)  – September 3, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the European Patent Office (EPO) has granted the company patent number EP1893747, entitled
View HTML
Toggle Summary FDA Clears Mayo Clinic for Manufacture of NurOwn and Participation in BrainStorm’s Phase 2 ALS Trial
NEW YORK, PETACH TIKVAH (Israel)  – August 18, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Mayo Clinic Human Cellular Therapy
View HTML
Toggle Summary BrainStorm Receives Notice of Allowance on US Patent
NEW YORK, PETACH TIKVAH, (Israel) – July 28, 2014 –  BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, received Notice of Allowance from the United States Patent Office for Patent Application 12/994,761, titled
View HTML
Toggle Summary BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical Trial
NEW YORK & PETACH TIKVAH, Israel – July 15, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the University of Massachusetts (UMass) Memorial Medical Center in Worcester, MA will begin
View HTML
Toggle Summary BrainStorm Announces Publication of Preclinical Multidose Study of NurOwn
NEW YORK, PETACH TIKVAH –  July 11, 2014 –  BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today publication of an important preclinical study in the journal Clinical and Translational Medicine . This
View HTML
Toggle Summary BrainStorm and Octane Successfully Construct a Bioreactor Prototype For Industrial-Scale Manufacturing of NurOwn Stem Cells
NEW YORK, PETACH TIKVAH, (Israel) and KINGSTON (Canada) –  June 27, 2014 –  BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian firm that focuses on clinical systems for cell and
View HTML
Toggle Summary Brainstorm Cell Therapeutics Raises $10.5 Million in Private Placement Financing
NEW YORK, NY and PETAH TIKVA, ISRAEL, June 13, 2014 -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System therapeutics, today announced that it has entered into definitive agreements with a group of investors,
View HTML
Toggle Summary June 10, 2014 Conference Call
Click here for a recording of the June 10, 2014 Shareholder's Conference Call
View HTML
Toggle Summary BrainStorm Expands Pipeline with Initiation of Pre-clinical Study in Autism
NEW YORK & PETACH TIKVAH, Israel – June 10, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has initiated a study in a mouse model of autism at the Felsenstein Medical Research Center,
View HTML
Toggle Summary BrainStorm Cell Therapeutics Appoints Tony Fiorino, MD, PhD as Chief Executive Officer
NEW YORK & PETACH TIKVAH, Israel—June 9, 2014 -- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has appointed Tony Fiorino, MD, PhD as its new Chief Executive Officer (CEO). Dr.
View HTML
Toggle Summary First Patient Enrolled in BrainStorm's Phase II ALS Trial at Massachusetts General Hospital
NEW YORK & PETACH TIKVAH, Israel – June 6, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital (MGH) in
View HTML
Toggle Summary BrainStorm Hosting Conference Call to Update Shareholders on Major Developments
NEW YORK & PETACH TIKVAH, Israel – June 5, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, June 10, 2014 at 8:45 a.m.
View HTML
Toggle Summary Positive Interim Phase IIa ALS Data with BrainStorm's NurOwn™ Presented at Joint Congress of European Neurology
Latest Results Reinforce Earlier Study Data NEW YORK & PETACH TIKVAH, Israel – June 2, 2014 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced that interim results from the Company's Phase IIa ALS trial conducted at Hadassah Medical Center in Jerusalem, Israel were presented
View HTML
Toggle Summary BrainStorm Announces Redemption of Outstanding Warrants for Cash
NEW YORK & PETACH TIKVAH, Israel – May 29, 2014 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) announced today that it has entered into agreements with holders of warrants originally issued in the Company’s August 16, 2013 public offering, to repurchase outstanding warrants to purchase an
View HTML
Toggle Summary BrainStorm to Present Phase IIa ALS Clinical Trial Data at the Joint Congress of European Neurology
NEW YORK & PETACH TIKVAH, Israel – May 27, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will be presenting initial results from its Phase IIa ALS trial at the Joint Congress of European Neurology in Istanbul,
View HTML
Toggle Summary BrainStorm Cell Therapeutics Presenting at Multiple Upcoming Conferences
New York, NY and Petach Tikvah, Israel, May 19, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it is presenting at the following scientific and industry conferences this month.
View HTML
Toggle Summary FDA Approves Commencement of BrainStorm's Phase II ALS Clinical Trial in U.S.
NEW YORK & PETACH TIKVAH, Israel – April 28, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the US Food and Drug Administration (FDA) has approved commencement of its Phase II clinical trial
View HTML
Toggle Summary April 28, 2014 Conference Call
Click here for a recording of the April 28, 2014 Shareholder's Conference Call
View HTML
Toggle Summary BrainStorm Announces Exchange of Outstanding Warrants
NEW YORK & PETACH TIKVAH, Israel – April 25, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI) announced today that it has entered into agreements with holders of warrants originally issued in the Company’s August 16, 2013 public offering, to exchange outstanding warrants to purchase an aggregate
View HTML
Toggle Summary BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
NEW YORK & PETACH TIKVAH, Israel – April 22, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will hold a conference call on Monday, April 28, 2014 at 8:45 a.m.
View HTML
Toggle Summary BrainStorm Granted Additional US Patent for its Autologous Stem Cell Technology
NEW YORK & PETACH TIKVAH, (Israel) – April 10, 2014 – BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the company an additional patent for its
View HTML
Toggle Summary BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
NEW YORK & PETACH TIKVAH, Israel – March 25, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA
View HTML
Toggle Summary BrainStorm Granted Key US Patent for its Autologous Stem Cell Technology
NEW YORK & PETACH TIKVAH, (Israel) – March 24, 2014 – BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the U.S. Patent and Trademark Office has granted the company a key patent for its autologous
View HTML
Toggle Summary BrainStorm to Present Latest Company Developments at Regen Med Investor Day March 26 in New York
NEW YORK & PETACH TIKVAH, Israel – March 18, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Mr. Chen Schor, Executive Board Member, will present the company's latest developments at the 2 nd
View HTML
Toggle Summary BrainStorm Receives Additional $600,000 Non-Dilutive Grant from Israel’s Office of the Chief Scientist
NEW YORK & PETACH TIKVAH, (Israel) – February 25, 2014 –  BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. was awarded an additional non-dilutive grant from
View HTML
Toggle Summary BrainStorm Issues Annual Letter to Shareholders
NEW YORK & PETACH TIKVAH, Israel—February 4, 2014-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today issued a Letter to Shareholders from its President, Mr. Chaim Lebovits, summarizing the company’s major
View HTML
Toggle Summary BrainStorm Receives US Notice of Allowance for its Key Stem Cell Technology Patent
NEW YORK & PETACH TIKVAH, (Israel) – February 3, 2014 – BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S.
View HTML
Toggle Summary January 30, 2014 Conference Call
Click here for a recording of the January 30, 2014 Shareholder's Conference Call
View HTML
Toggle Summary BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn Manufacturing
NEW YORK & PETACH TIKVAH, Israel – January 29, 2014 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Mayo Clinic in Rochester, Minnesota to conduct its
View HTML
Toggle Summary BrainStorm Hosting a Conference Call with Clinical Trial Advisors in Israel US and Brazil to Update Shareholders on Current Developments
NEW YORK & PETACH TIKVAH, (Israel) – January  15, 2014 – BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Thursday, January 30, 2014 at 8:45 a.m.
View HTML
Toggle Summary BrainStorm Receives United States Patent Office Notice of Allowance for its Stem Cell Technology
NEW YORK & PETACH TIKVAH, (Israel) – January  13, 2014 – BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received a Notice of Allowance from the U.S.
View HTML
Toggle Summary BrainStorm Receives Notice of Allowance to Grant European Patent Covering its Stem Cells for the Treatment of CNS Diseases
NEW YORK & PETACH TIKVAH, (Israel) – January  8, 2014 – BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has received notification from the European Patent Office (EPO) of its intention to grant
View HTML
Toggle Summary Significant Clinical Findings in ALS Patient Treated with BrainStorm's NurOwn Featured in “Muscle and Nerve”
NEW YORK & PETACH TIKVAH, (Israel) – January 6, 2014 – BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced the upcoming publication of a case report on an individual patient treated with the company’s
View HTML
Toggle Summary BrainStorm Receives $800,000 Non-Dilutive Grant from Israel’s Office of the Chief Scientist
NEW YORK & PETACH TIKVAH, (Israel) – December 11, 2013 –  BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. was awarded a $800,000 non-dilutive grant from
View HTML
Toggle Summary Preliminary Findings of BrainStorm's Phase IIa Study Reported as "Extremely Optimistic"
NEW YORK & PETACH TIKVAH, Israel – December 10, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Prof. Dimitrios Karussis, Principal Investigator of the Company's clinical trials at Hadassah
View HTML
Toggle Summary BrainStorm Cell Therapeutics Presents at the 24th International Symposium on ALS/MND
NEW YORK & PETACH TIKVAH, Israel, December 5, 2013, BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Prof. Dimitrios Karussis, Principal Investigator of the Company's clinical trials at Hadassah
View HTML
Toggle Summary November 19, 2013 Conference Call
Click here for a recording of the November 19, 2013 Shareholder's Conference Call
View HTML
Toggle Summary BrainStorm Cell Therapeutics Will Host a Conference Call to Update Shareholders on Recent Positive Company Developments
NEW YORK & PETACH TIKVAH, Israel – November 12, 2013 --BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, November 19, 2013 at 8:45 a.m.
View HTML
Toggle Summary BrainStorm to Initiate Study for Multiple Sclerosis at Hadassah Medical Center
New York, NY and Petach Tikvah, Israel, October 15, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will initiate a pre-clinical study for Multiple Sclerosis (MS) at the Hebrew University
View HTML
Toggle Summary BrainStorm to Present at Multiple Scientific Conferences in October
New York, NY and Petach Tikvah, Israel, October 8, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it is presenting at multiple scientific conferences this month.
View HTML
Toggle Summary BrainStorm to Present at 2013 Stem Cell Meeting on the Mesa Organized by CIRM, ARM and Sanford Consortium
New York, NY and Petach Tikvah, Israel, October 7, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dr. Adrian Harel, Director R&D, will present at the 3rd Annual Regen Med Partnering Forum,
View HTML
Toggle Summary BrainStorm Launches US Activities for Its Multi-Center ALS Clinical Trial
New York, NY and Petach Tikvah, Israel, October 1, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has launched its activities in the US in preparation for its Phase IIa multi-center
View HTML
Toggle Summary August 20, 2013 Conference Call
Click here for a recording of the August 20, 2013 Shareholder's Conference Call
View HTML
Toggle Summary BrainStorm Cell Therapeutics Will Host a Conference Call to Update Shareholders on Recent Company Developments
NEW YORK & PETACH TIKVAH, Israel -- August 14, 2013 --BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI), leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, August 20, 2013 at 8:45 a.m.
View HTML
Toggle Summary BrainStorm Cell Therapeutics Announces Pricing of Underwritten Public Offering
NEW YORK, NY and PETAH TIKVA, ISRAEL—August 13, 2013 –BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) today announced the pricing of a $4.0 million underwritten public offering of 23,529,411 units at a public offering price of $0.17 per unit, with each unit consisting of one share of its common
View HTML
Toggle Summary BrainStorm Submits Favorable Interim Safety Report for Second Group of Patients in its Phase IIa Dose-EscalatingTrial of NurOwn™ in ALS
NEW YORK & PETACH TIKVAH, (Israel) – August 1, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has submitted a favorable safety report to the hospital Helsinki Committee (IRB) for the
View HTML
Toggle Summary BrainStorm’s NurOwn Cell Therapy Receives Orphan Drug Designation in the European Union for ALS
NEW YORK & PETACH TIKVAH, (Israel) – July 29, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the European Commission has granted Orphan Drug Designation for NurOwn™, the Company's stem cell
View HTML
Toggle Summary BrainStorm Signs Memorandum of Understanding with PRC Clinical for US Clinical Trial Management
NEW YORK & PETACH TIKVAH, (Israel) – June 26, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a Memorandum of Understanding (MOU) with PRC Clinical™, a Contract Research
View HTML
Toggle Summary BrainStorm Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 Patients
NEW YORK & PETACH TIKVAH, (Israel) – June 10, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has successfully treated the eighth patient in its ongoing Phase IIa ALS clinical trial at the
View HTML
Toggle Summary BrainStorm Submits Favorable Interim Safety Report for First Group of Patients in its Phase IIa Dose-EscalatingTrial
NEW YORK & PETACH TIKVAH, (Israel) – June 5, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has submitted a favorable safety report to the hospital Helsinki Committee (IRB) for the first
View HTML
Toggle Summary BrainStorm Receives 1.2 Million NIS Grant from Israel’s Office of the Chief Scientist
NEW YORK & PETACH TIKVAH, (Israel) – June 4, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company has received the third installment of the 2013 grant from Israel’s Office of the Chief
View HTML
Toggle Summary BrainStorm Announces CEO Interview with the Wall Street Analyst
New York, NY and Petach Tikvah, Israel, May 23, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that The Wall Street Analyst conducted an audio interview yesterday with the Company's Chief Executive
View HTML
Toggle Summary BrainStorm Provides Update on Clinical Trial and Scientific Conference Activities
New York, NY and Petach Tikvah, Israel, May 21, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today provided an update on the company’s current and upcoming clinical trial and scientific conference activities.
View HTML
Toggle Summary BrainStorm Presenting at Several Scientific and Investment Conferences
NEW YORK & PETACH TIKVAH, Israel – April 10, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the company will be presenting at several upcoming scientific and investment conferences.
View HTML
Toggle Summary BrainStorm Partners with Dana-Farber for NurOwn™ Production in Phase II ALS Clinical Trial
NEW YORK & PETACH TIKVAH, Israel – April 8, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Dana-Farber Cancer Institute (“Dana-Farber”) has entered into an agreement to provide
View HTML
Toggle Summary BRAINSTORM PROVIDES RECENT CORPORATE AND CLINICAL DEVELOPMENT UPDATE
·         NurOwn™ Clinical Trial Suggests Efficacy In Patients with ALS ·         Mayo Clinic Joins MGH and UMass to Conduct Phase II Clinical Trial of BrainStorm’s NurOwn™ in ALS New York, NY and Petach Tikvah, Israel, March 25, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading
View HTML
Toggle Summary RESULTS OF NUROWN™ CLINICAL TRIAL SUGGEST EFFICACY IN ALS PATIENTS
Data Indicate Initial Clinical Benefit in Overall Clinical and Respiratory Function New York, NY and Petach Tikvah, Israel – March 21, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today reported some of the
View HTML
Toggle Summary Phase II ALS Clinical Trial with BrainStorm Cell Therapeutics’ NurOwn™ to be Expanded to a Third Premiere U.S. Clinical Site
NEW YORK & PETACH TIKVAH, Israel – March 18, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Mayo Clinic in Rochester, Minnesota has entered into a Memorandum of Understanding with the intent
View HTML
Toggle Summary BrainStorm Cell Therapeutics Presents Breakthrough Phase I/II ALS Clinical Data at the American Academy of Neurology Annual Meeting
American Academy of Neurology's Annual Meeting Being Held March 16-23 at the San Diego Convention Center BrainStorm Presentation:  Emerging Science Session on Wednesday, March 20, 2013 NEW YORK & PETACH TIKVAH, Israel – March 13, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading
View HTML
Toggle Summary BrainStorm Cell Therapeutics Presents at the 11th International Conference On Alzheimer's and Parkinson’s Disease
NEW YORK & PETACH TIKVAH, Israel – March 8, 2013 – BrainStorm Cell Therapeutics (OTCQB: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today a poster presentation of clinical and scientific data at the 11th International Conference on Alzheimer’s
View HTML
Toggle Summary Rasheda Ali on National and Local News: BrainStorm’s ALS Clinical Trial Results Exceeded Expectations
NEW YORK & PETACH TIKVAH, Israel—February 27, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the company was recently featured on national and local news, as well as Fox News.
View HTML
Toggle Summary BrainStorm to Present at the 8th Annual New York Stem Cell Summit
NEW YORK & PETACH TIKVAH, Israel—February 13, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it will be presenting at the 8 th Annual New York Stem Cell Summit on Tuesday, February 19 th at 2:00
View HTML
Toggle Summary BrainStorm Announces Private Equity Financing of $250,000 with Individual Private Investor
NEW YORK & PETACH TIKVAH, Israel--(February 11, 2013)-- BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a $250,000 Common Stock purchase agreement with an individual private
View HTML
Toggle Summary First Patient Begins Treatment in BrainStorm’s Phase IIa Trial for ALS
NEW YORK & PETACH TIKVAH, Israel—February 4, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Company’s Phase IIa dose-escalating clinical trial for
View HTML
Toggle Summary BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
NEW YORK & PETACH TIKVAH, Israel—January 28, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Mr. Alon Natanson as its new Chief Executive Officer (CEO). Mr.
View HTML
Toggle Summary BrainStorm’s CEO Issues Annual Letter to Shareholders
NEW YORK & PETACH TIKVAH, Israel—January 23, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that its CEO, Dr. Adrian Harel, has issued an Annual Letter to Shareholders summarizing the company’s
View HTML
Toggle Summary January 14, Conference Calls
Please click here: Conference call in English Conference call in Hebrew
View HTML
Toggle Summary BrainStorm Establishes Safety of Repeat Doses of NurOwn in Mice; Pre-clinical study conducted at GLP-compliant Harlan laboratories
NEW YORK & PETACH TIKVAH, Israel—January 10, 2013 -- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it has successfully completed a 12-week repeat dose toxicity study with its NurOwn cells in mice.
View HTML
Toggle Summary Brainstorm Achieves Important New Development for Commercialization of NurOwn
NEW YORK & PETACH TIKVAH, Israel—January 9, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has achieved a new breakthrough for commercialization of its stem cell therapy candidate,
View HTML
Toggle Summary BrainStorm’s Clinical Trial is Fast-Tracked to Phase IIa,Representing a Major Milestone for the Company
NEW YORK & PETACH TIKVAH, Israel—January 7, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Israeli Ministry of Health has fast-tracked its current Phase I/II ALS safety trial to a Phase
View HTML
Toggle Summary BrainStorm Announces New Shareholders Conference Call Date to Discuss Upcoming Positive Developments
NEW YORK & PETACH TIKVAH, Israel—January 3, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that is has rescheduled its previously planned shareholders conference call.
View HTML
Toggle Summary BrainStorm and Octane to Develop Revolutionary Bioreactor-Based NurOwn Stem Cells Production Process
NEW YORK & PETACH TIKVAH, Israel—December 17, 2012-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed an agreement with Octane Biotech of Kingston, Ontario, to jointly develop a
View HTML
Toggle Summary BrainStorm Receives 3 Million NIS Grant from Israel’s Office of the Chief Scientist
NEW YORK & PETACH TIKVAH, (Israel) – December 12, 2012 –  BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. was awarded a 3 million NIS grant from Israel’s
View HTML
Toggle Summary BrainStorm’s Outstanding ALS Clinical Data Chosen to Kick-Off the Israel Neurological Association Meeting
New York and Petach Tikva, Israel (December 11, 2012) - BrainStorm Cell Therapeutics  (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is proud to announce that its positive Phase I/II ALS clinical trial data was selected as the opening
View HTML
Toggle Summary BrainStorm Deferring Shareholders Conference Call in Anticipation of Upcoming Developments
NEW YORK & PETACH TIKVAH, Israel, Dec 10, 2012 (BUSINESS WIRE) -- BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it is deferring its shareholders conference call scheduled for December 11, 2012, in
View HTML
Toggle Summary BrainStorm Cell Therapeutics Inc. Will Host a Conference Call to Update Shareholders on Upcoming Trial and Other Exciting Developments
Ticker Symbol:OTC.QB:BCLI NEW YORK & PETACH TIKVAH, Israel -- (Business Wire) -- BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that its senior management will hold a conference call on Tuesday, December 11,
View HTML
Toggle Summary Rasheda Ali, Daughter of Legendary Muhammad Ali and Advisory Board Member of BrainStorm, Visits Company Laboratories and Clinical Trials Site at Hadassah Medical Center in Jerusalem, Israel
NEW YORK & PETACH TIKVAH, Israel—August 13, 2012 -- BrainStorm Cell Therapeutics (OTC: BCLI), a leading developer of adult stem cell technologies and CNS therapeutics, announced that Rasheda Ali Walsh, daughter of the legendary Muhammad Ali, visited the Company’s laboratories as well as its
View HTML
Toggle Summary July 25th, 2012 Conference calls
Please click here: Conference call in English Conference call in Hebrew
View HTML
Toggle Summary BrainStorm Cell Therapeutics Inc. Will Host a Conference Call to Update Shareholders on Recent Developments
BrainStorm Cell Therapeutics Inc. (OTC:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that its senior management will hold a conference call on Wednesday, July 25, 2012 at 8:00 a.m. EDT in Hebrew and at 8:45 a.m. EDT in English. Dr.
View HTML
Toggle Summary BrainStorm Reports Outstanding ALS Interim Clinical Trial Results
New York and Petach Tikva, Israel (July 23, 2012) - BrainStorm Cell Therapeutics (OTC:BCLI) announced today that it has completed the planned interim safety review of its Phase I/II ALS (Amyotrophic Lateral Sclerosis) clinical trial, indicating that autologous transplantation of the Company's cell
View HTML
Toggle Summary BrainStorm Closes $5.7 Million Public Offering
NEW YORK & PETACH TIKVAH, (Israel) July 19, 2012 -- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that it completed a registered public offering of 19,818,972 shares of common
View HTML
Toggle Summary BrainStorm Announces Pricing of Public Offering of Common Stock and Warrants
NEW YORK & PETACH TIKVAH, (Israel) July 17, 2012 -- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced the pricing of a registered public offering of shares of common stock and
View HTML
Toggle Summary Israeli Channel 2 reports: Dramatic Change in Patient with ALS and MG following Compassionate Use of BrainStorm’s Nurown™ Cell Therapy
NY, Petach Tikva, July 2, 2012. -- BrainStorm Cell Therapeutics Inc. (OTC BB: BCLI), Israeli Channel 2 TV interviewed today a patient suffering from Myasthenia Gravis (MG) and recently diagnosed with ALS. The patient reported that he has experienced visible improvement in his speech, walking,
View HTML
Toggle Summary BrainStorm Receives 1.3 Million NIS Grant from Israel’s Office of the ChiefScientist Dr. Adrian Harel promoted to CEO of Brainstorm
NEW YORK & PETACH TIKVAH, (Israel) – June 14 th 2012. BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of adult stem cell therapeutics targeting Central Nervous System (CNS) neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd.
View HTML
Toggle Summary BrainStorm Cell Therapeutics Issues CEO Update to Shareholders
-- ( BUSINESS WIRE )-- BrainStorm Cell Therapeutics (OTC BB: BCLI), a developer of adult stem cell technologies and CNS therapeutics, has issued a CEO update to shareholders and investors, with a review of recent accomplishments. Acting CEO Dr. Adrian Harel reported on the following recent company
View HTML
Toggle Summary BrainStorm Cell Therapeutics Expands Pipeline with the Initiation of a Study for Multiple Sclerosis Proposed Trial Will Build on NurOwn™ Platform to Meet Unmet Needs of Patients with Neurodegenerative Disorders
NEW YORK & PETACH TIKVAH, ISRAEL--( BUSINESS WIRE )-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of adult stem cell technologies and CNS therapeutics, announces plans to initiate a preclinical study assessing the efficacy of its NurOwn™ stem cell technology in patients with
View HTML
Toggle Summary Nature: BrainStorm's NurOwn™ Stem Cell Technology Offers Hope for Treating Huntington Disease
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Nature Reviews Neurology, a Nature Publishing Group Journal, highlighted recently published preclinical research results indicating that stem
View HTML
Toggle Summary BrainStorm Featured on CNBC
NEW YORK & PETACH TIKVAH, Israel--( BUSINESS WIRE )-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of innovative stem cell technologies for neurodegenerative disorders, announced that NurOwn™, its autologous stem cell therapy for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's
View HTML
Toggle Summary Experimental Neurology Journal: BrainStorm's NurOwn™ Stem Cell Technology Shows Promise for Treating Huntington's Disease
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s
View HTML
Toggle Summary BrainStorm Announces Clinical Data Supporting Safety and Efficacy of NurOwn™ Based on Initial Patient Results
NEW YORK & PETACH TIKVAH, (Israel) January 17, 2012 -- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, today announced that the data from the initial patients in its ALS Phase I/II human clinical
View HTML
Toggle Summary Professor Karussis: BrainStorm's Study Offers the Biggest Hope to Stop Disease Progression in ALS Patients
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and CNS therapeutics, today announced that patients from across the globe are demanding to be included in the pioneering clinical study started earlier this year at Jerusalem’s Hadassah
View HTML
Toggle Summary Brainstorm's Clinical Trials Featured on the Israeli Radio Popular Morning News (Yoman Haboker)
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of innovative adult stem cell technologies for debilitating neurodegenerative disorders, today announced that BrainStorm’s Phase I/II clinical trial for amyotrophic lateral sclerosis (ALS) at the Hadassah Medical Center, was featured on
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reviews 3 Quarters of 2011 Achievements
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors. Since the beginning of the Phase I/II clinical trial for BrainStorm’s autologous adult stem cell therapy
View HTML
Toggle Summary BrainStorm Receives Grant from Israel’s Office of the Chief Scientist
NEW YORK & PETACH TIKVAH, (Israel) -- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell therapeutics targeting Central Nervous System (CNS) diseases,today announced that it received notice from Israel’s Office of the Chief Scientist (OCS) of its commitment
View HTML
Toggle Summary Ministry of Health Approves BrainStorm’s NurOwn™ for the First Clinical Trial of Adult Stem Cell Therapy for ALS
Brainstorm and Hadassah to Conduct Trial with Brainstorm Cell Therapeutics’ NurOwn™ New York and Petach Tikvah, Israel, 17 May, 2011 – BrainStorm Inc. (OTC BB: BCLI), a leading developer of adult stem cell technologies and therapeutics, and Hadasit, the technology transfer company of the Hadassah
View HTML
Toggle Summary BrainStorm Signs MOU for Collaboration with Massachusetts General Hospital and University of Massachusetts Medical School to Conduct Human Clinical Trials in the United States
NEW YORK & PETACH TIKVAH, Israel--( BUSINESS WIRE )-- BrainStorm Cell Therapeutics Inc. (BCLI.OB), a developer of adult stem cell technologies and CNS therapeutics, announced today that it has entered into a Memorandum of Understating with Massachusetts General Hospital and the University of
View HTML
Toggle Summary BrainStorm Initiates Clinical Trials and Holds Successful Shareholders Meeting
NEW YORK & PETACH TIKVAH, Israel--( BUSINESS WIRE )-- BrainStorm Cell Therapeutics (OTCBB: BCLI), a developer of adult stem cell technologies and CNS therapeutics, announced today that together with the Hadassah Medical Organization, a successful study initiation/clinical trial kickoff meeting was
View HTML
Toggle Summary BrainStorm Intends to Adjourn Annual Meeting of Stockholders until June 10, 2011
NEW YORK & PETACH TIKVAH, Israel--( BUSINESS WIRE )--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics announced today that, immediately upon convening its Annual Meeting of Stockholders on Thursday, June 9, 2011, the Company
View HTML
Toggle Summary Rasheda Ali to Discuss BrainStorm on Fox News Today
Jun. 1, 2011 (Business Wire) -- BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that Rasheda Ali, a member of BrainStorm’s advisory board and revered author and daughter of renowned boxer Muhammad Ali, will
View HTML
Toggle Summary Ministry of Health Approves BrainStorm’s NurOwn™ for the First Clinical Trial of Adult Stem Cell Therapy for ALS
Brainstorm and Hadassah to Conduct Trial with Brainstorm Cell Therapeutics’ NurOwn™   New York and Petach Tikvah, Israel, 17 May, 2011 – BrainStorm Inc. (OTC BB: BCLI), a leading developer of adult stem cell technologies and therapeutics, and Hadasit, the technology transfer company of the Hadassah
View HTML
Toggle Summary BrainStorm to Open Today’s Trading on the OTCBB
New York and Petach Tikvah, Israel – May 9, 2011 – BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it will open today’s trading session on the Over-the Counter Bulletin Board (“OTCBB”).
View HTML
Toggle Summary Former Deloitte Executive Joins BrainStorm Cell Therapeutics as Independent Director and Chairman of the Audit Committee
New York and Petach Tikvah, Israel – April 5, 2011 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that Mordechai (Moti) Friedman, CPA, a former Deloitte Brightman Almagor executive and deputy chairman, has
View HTML
Toggle Summary BrainStorm Cell Therapeutics Reviews First Quarter of 2011 Achievements
New York and Petach Tikvah, Israel – March 24, 2011 – BrainStorm Cell Therapeutics Inc. (BCLI.PK or BCLI.QB formerly BCLI.OB), a leading developer of adult stem cell technologies and therapeutics, today provided a review of recent accomplishments for shareholders and investors.
View HTML
Toggle Summary Andrew Card Joins BrainStorm Cell Therapeutics’ Business Advisory Board
Second-longest serving White House Chief of Staff, Andrew H. Card, Jr., was appointed in the presidential administration of George W. Bush   New York and Petach Tikvah, Israel – March 14, 2011 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies and
View HTML
Toggle Summary BrainStorm Cell Therapeutics Raises $3.6 Million from Institutional and Private Investors in Equity Financing
New York and Petach Tikvah, Israel – February 28, 2011 – BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into securities purchase agreements with certain institutional and other investors in
View HTML
Toggle Summary BrainStorm’s NurOwn™ Stem Cell Technology Shows Promise for Treating Sciatic Nerve Injury
Positive Preclinical Results Published in Stem Cell Reviews and Reports NEW YORK & PETACH TIKVAH, Israel--( BUSINESS WIRE )-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that intramuscular transplantation of
View HTML
Toggle Summary BrainStorm Receives FDA Orphan Drug Designation for NurOwn™ in the Treatment of Amyotrophic Lateral Sclerosis
NEW YORK & PETACH TIKVAH, Israel--( BUSINESS WIRE )-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s NurOwn™
View HTML
Toggle Summary BrainStorm Announces Private Equity Financing of $250,000 With Single Institutional Investor
NEW YORK & PETACH TIKVAH, Israel--( BUSINESS WIRE )-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has signed a $250,000 common stock purchase agreement with a single accredited investor.
View HTML
Toggle Summary BrainStorm Appoints Dr. Adrian Harel as Chief Operating Officer and Acting Chief Executive Officer
New York and Petach Tikvah, Israel – January xx, 2011 – BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, today announced the recruitment of a highly experienced drug developer, Adrian Harel, Ph.D., as its Chief Operating Officer
View HTML
Toggle Summary BrainStorm Announces Resignation of CEO and Appointment of Former Consul General of Israel in New York, Ambassador Alon Pinkas, to the Board of Directors
NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, today announced that Abraham (Rami) Efrati, Chief Executive Officer, is resigning from his position at the Company in order to
View HTML
Toggle Summary BrainStorm Receives Approval to Begin Clinical Trial of Adult Stem Cell Therapy in Patients with ALS
Building on Nearly Five Years of Research, BrainStorm is the First Company to Receive Clearance from the Israeli Ministry of Health for a Differentiated Stem Cell-Based Therapy in Israel New York and Petach Tikvah, Israel – October 11, 2010 – BrainStorm Cell Therapeutics Inc.
View HTML
Toggle Summary BrainStorm Engages Poalim IBI as its Financial Advisor
Poalim IBI will also assist the company with exploring various options for listing on the Tel Aviv Stock Exchange NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, today
View HTML
Toggle Summary BrainStorm Retains Life Sciences Advisory Firm
Company also provides clinical trial status update New York and Petach Tikvah, Israel – July 26, 2010 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, today announced that it has retained MD Becker Partners LLC, a boutique
View HTML
Toggle Summary Liat Sossover Joins BrainStorm Cell Therapeutics as CFO
New York and Petach Tikvah, Israel – June 22, 2010 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, today announced that Liat Sossover, CPA is joining the Company as its Chief Financial Officer. Ms.
View HTML
Toggle Summary BrainStorm To Present at ILSI-Biomed Israel 2010
New York and Petach Tikvah, Israel – June 11, 2010 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics today announced that Rami Efrati, BrainStorm’s CEO, will be presenting at the 9th National Life Science and Technology Week
View HTML
Toggle Summary BrainStorm To Present at Inaugural Stem Cell Conference Hosted by National Securities Corporation and MD Becker Partners
New York and Petach Tikvah, Israel – June 1, 2010 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics today announced that Rasheda Ali, a member of BrainStorm’s advisory board and Professor Eldad Melamed, BrainStorm’s Chief Medical
View HTML
Toggle Summary BrainStorm To Present At World Stem Cells and Regenerative Medicine Congress
New York and Petach Tikvah, Israel – May 12, 2010 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics is pleased to announce that Dr. Avinoam Kadouri, BrainStorm’s Chief Technology Advisor, has been invited to act as a Chairman at
View HTML
Toggle Summary BrainStorm Announces Significant Milestones Achieved and 2009 Review
New York and Petach Tikvah, Israel – May 11, 2010 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics provided today a review of fiscal 2009 and an update of its significant milestones achieved.
View HTML
Toggle Summary Professor Avi Israeli Joins BrainStorm as Chairman of the Board of Directors
New York and Petach Tikvah, Israel – April 14, 2010 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics is pleased to announce that Professor Avi Israeli is joining the company as Chairman of the Board of Directors.
View HTML
Toggle Summary BrainStorm Enters Into Collaborative Agreement With Hadassah to Conduct Clinical Trials
New York and Petach Tikvah, Israel – February 22, 2010 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is extremely pleased to announce that it has entered into a collaborative agreement with Hadassah Medical Center to conduct
View HTML
Toggle Summary BrainStorm Secures Funding to Conduct Clinical Trials
New York and Petach Tikvah, Israel – February 17, 2010 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it has entered into agreements with three investors with each investing $500,000 for a total of
View HTML
Toggle Summary Israeli Minister of Industry, Trade and Labor and Israeli Chief Scientist Visit BrainStorm
New York and Petach Tikvah, Israel – January 26, 2010 - BrainStorm Cell Therapeutics Inc.(OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it received a visit today by the Israeli Minister of Industry, Trade and Labor, Mr.
View HTML
Toggle Summary Israeli Minister of Science and Technology Visits Brainstorm
New York and Petach Tikvah, Israel – January 12, 2010 - BrainStorm Cell Therapeutics Inc.(OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that it received a visit yesterday by the Israeli Minister of Science and Technology, Professor Daniel
View HTML
Tools
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds